Please try another search
For the nine months ended 30 September 2011, PoniardPharmaceuticals, Inc. revenues remained flat at $0K. Netloss applicable to common stockholders decreased 57% to$11M. Revenues reflect market conditions. Lower net lossreflects Research and development decrease of 87% to $1.1M(expense), Interest expense decrease of 96% to $70K(expense), Restructuring decrease from $1.6M (expense) to$0K.
Period Ending: | Sep 30, 2011 | Jun 30, 2011 | Mar 31, 2011 | Dec 31, 2010 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 303.15 | 0 |
Gross Profit | 27.62 | |||
Operating Income | -3.75 | -3.84 | -37.18 | -4.71 |
Net Income | -3.77 | -3.86 | -37.39 | -5.17 |
Period Ending: | Sep 30, 2011 | Jun 30, 2011 | Mar 31, 2011 | Dec 31, 2010 |
---|---|---|---|---|
Total Assets | 7.74 | 9.99 | 4533.81 | 11.64 |
Total Liabilities | 4.62 | 3.71 | 2420.6 | 3.19 |
Total Equity | 3.12 | 6.28 | 2113.21 | 8.45 |
Period Ending: | Sep 30, 2011 | Jun 30, 2011 | Mar 31, 2011 | Dec 31, 2010 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -5.41 | -3.7 | 39.07 | -24.28 |
Cash From Investing Activities | 3.02 | 3.02 | -141.97 | 24.02 |
Cash From Financing Activities | 3.09 | 3.09 | 114.67 | -14.4 |
Net Change in Cash | 0.7 | 2.41 | 11.17 | -14.65 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review